Outcome of Alzheimer's disease: Potential impact of cholinesterase inhibitors

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 61, Issue 5, 2006, Pages 516-520

  Gillette Guyonnet, Sophie ^a,c,d   Andrieu, Sandrine ^b,c   Cortes, Frédéric ^a,c   Nourhashemi, Fati ^a,c   Cantet, Christelle ^a,b   Ousset, Pierre Jean ^a   Reynish, Emma ^a   Grandjean, Hélène ^b   Vellas, Bruno ^a,b  

^a CHU PURPAN   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c INSERM   (France)

^d Serv Univ Psychiat l'Enfant l'A   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL EXAMINATION; COGNITION; DAILY LIFE ACTIVITY; DRUG MARKETING; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INSTITUTIONALIZATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; NUTRITIONAL STATUS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 33646923102     PISSN: 10795006     EISSN: None     Source Type: Journal    
DOI: 10.1093/gerona/61.5.516     Document Type: Article

References (29)

1. Fratiglioni L, Launer LJ, Andersen K, et al. Incidence ol dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54:S10-S15.
2. Rocca WA, Hofman A, Brayne C, et al. Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1980-1990 prevalence findings. The EURODEM-Prevalence Research Group. Ann Neurol. 1991;30:381-390.
3. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose taerine in patients with Alzheimer's disease. JAMA. 1994;271:985-991.
4. Rogers SL, Farlow MR, Doody RS, et al. A 24-week double-blind placebo controlled trial of donepezil in patients with Alzbeimer's disease. Neurology. 1998;50:136-145.
5. Tariol PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc. 2001;49:1590-1599.
6. Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999;318:633-638.
7. Raskind MA, Peskind ER. Alzheimer's disease and related disorders. Med Clin North Am. 2001;85:803-817.
8. Tariol PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 2000;54:2269-2276.
9. Wilcock GK, Lilienfield S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ. 2000;321:1445-1449.
10. Winblad B, Brodaty H, Gauthier S, et al. Pharmacotherapy of Alzheimer disease: is there need to redeline treatment success? Int J Geriatr Psychiatry. 2001;16:653-666.
11. Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease. Arch Neurol. 2001;58:427-433.
12. Rogers SL, Doody RS, Pratt RD, et al. Long-tenu efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicenter open-label study. Euro Neuropsychopharmacol. 2000;10:195-203.
13. Lopez OL, Becker JT, Wisniewski S, et al. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002;72:310-314.
14. AD 2000 Collaborative Group. Long term donepezil treatment in 565 patients with Alzheimer's disease (AD 2000): randomised double-blind trial. Lancet. 2004;363:2105-2115.
15. Cortes F, Gillette-Guyonnet S, Nourhashemi F, et al. Recent data on the natural history of Alzheimer's disease: results from the REAL.FR study. J Nutr Health Aging. 2005;9:86-94.
16. Morris JC, Edland S, Clark C, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology. 1993;43:2457-2465.
17. White H, Pieper C, Schmader K, et al. Weight change in Alzheimer's disease. J Am Geriatr Soc. 1996;44:265-272.
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington (DC): APA; 1997.
19. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
20. Folstein MF, Folstein SE, Mc Hugh PR. Mini-Mental-Test: a practical method for grading the cognitive state of patient for the clinician. J Psychiatr Res. 1975;12:189-198.
21. Katz S, Ford AB, Moskowitz RW, et al. The index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914-919.
22. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179-186.
23. Vellas B, Guigoz Y, Garry PJ, et al. The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. Nutrition. 1999;15:116-122.
24. Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist. 1980;20:649-655.
25. O'Hara R, Thompson JM, Kraemer HC, et al. Which Alzheimer patients are at risk for rapid cognitive decline? J Geriatr Psychiatry Neurol. 2002;15:233-238.
26. Wallace H, Schwartz RS, LaCroix AZ, et al. Involuntary weight loss in older outpatients: incidence and clinical significance. J Am Geriatr Soc. 1995;43:329-337.
27. Lopez OL, Becker JT, Saxton J, et al. Alteration of clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. J Am Geriatr Soc. 2005;53:83-87.
28. Schneider LS. The future of cholinergic replacement therapy in Alzheimer's disease. Curr Opin Investig Drugs. 2000;2:427-437.
29. Gillette-Guyonnet S, Cortes F, Cantet C, et al. Long term cholinergic treatment is not associated with greater risk of weight loss during Alzheimer's disease: data from the French REAL.FR cohort. J Nutr Health Aging. 2005;9:69-74.